http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2597827-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6c404eb9afc1a3f2cee4e328f0d4b980 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 |
| filingDate | 2015-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d1416198c8f8e9fee5d16c62f0b82b5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92cef341b04105ea2df02da245521083 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_652352daaed18ba8fa7df9faef5ed8de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_952d2ce36a388a9ba83aabb0db0b064b |
| publicationDate | 2017-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2597827-B2 |
| titleOfInvention | Use of melatoninergic compounds to treat the ocular surface |
| abstract | Use of melatoninergic compounds to treat the ocular surface. # Increased tear secretion and / or improve the quality of the tear film by means of melatonin analogs such as agomelatine, 5-MCA-NAT and / or IIK7. The present invention describes a method for increasing tear secretion and / or improving the quality of the tear film by administering a pharmaceutical formulation of the agomelatine substance (N- [2- (7-methoxynaphthalen-1-yl) ethyl ] acetamide), 5-MCA-NAT (5-Methoxycarbonylamino-N-acetyltryptamine) and / or IIK7 (N-Butanoyl 2- (9-methoxy-6H-iso-indole [2,1-a] indole-11-yl ) -ethanamine)) and / or pharmaceutically acceptable salts thereof. The present invention also claims the use of agomelatine, 5-MCA-NAT and / or IIK7 and / or pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment and / or prevention of dry eye and / or diseases characterized by a decrease in tear secretion and / or a poor quality of the tear film. Said medicament is preferably administered topically, vehiculized or not by liposomes, and can be presented in different pharmaceutical forms, such as solutions, suspensions, emulsions, eye drops, liquid drops, liquid washes, contact lenses, gels, creams, ointments , ointments and sprays. |
| priorityDate | 2015-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 72.